12:16 PM EST, 11/25/2024 (MT Newswires) -- Rakovina Therapeutics ( RKVTF ) on Monday said it made a poster presentation poster showcasing initial results of its Deep Docking Artificial Intelligence (AI) drug discovery screening at the 29th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), which was held Nov. 21-24 in Houston, Texas.

The poster, titled "Utilizing Artificial Intelligence for the Discovery of Novel PARP1-Selective Inhibitors for Use Against Brain Tumors," highlighted rapid virtual multi-billion compounds screen to identify selective inhibitors of PARP-1, a key enzyme involved in DNA repair that plays a critical role in brain cancer progression, the company said.

Inhibition of PARP-1 has shown promise in sensitizing cancer cells to treatment.

The poster provided insight into the compounds' chemical properties affecting absorption, stability, and the ability to cross the blood-brain-barrier. The poster also profiled candidates that are predicted to have similar or improved PARP-1 selectivity and central nervous system (CNS) exposure compared with AZD9574, a novel development-stage blood-brain barrier penetrant and selective inhibitor of PARP-1, the company said

"Our team reached a significant milestone this fall with the initial results of our Deep Docking AI screening efforts, successfully evaluating billions of molecular structures within the projected timeframe described at the outset of the collaboration," said Executive Chairman Jeffrey Bacha. "Our innovative approach is not only improving the efficiency of drug discovery, but it is also enhancing the specificity and efficacy of potential therapeutics."

The company's shares were last seen up $0.005 to $0.06 on the TSX Venture Exchange.